Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDG2012
- Development stage
- Preclinical
- Lead developer
- MediGene
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MDG2012 is an investigational autologous T cell receptor-engineered T cell (TCR-T) therapy targeting the KRAS G12V mutation presented by HLA-A*03. It is being developed by Medigene for the treatment of solid tumors. The therapy leverages a highly specific, sensitive, and safe (3S) TCR platform designed to recognize and eliminate cancer cells harboring the KRAS G12V mutation in the context of HLA-A*03. As of August 2024, MDG2012 remains in preclinical development with lead selection expected in 2025[1][4][6][10].
02
Targets
KRAS G12V/HLA-A*03:01 (KRAS G12V peptide-HLA-A*03:01 complex)
Beyond the preview
Go deeper on MDG2012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDG2012.